Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esreboxetine vs Atomoxetine in Adult ADHD
NCT00562055Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of esreboxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Pfizer. Primary endpoint: Adult ADHD Investigator Symptom Rating Scale - Total Score at 4 weeks. Planned start Nov 2007; status: withdrawn.
02
Drugs
esreboxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00562055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562055.